Vorinostat in Combination with Lenalidomide and Dexamethasone in Lenalidomide Refractory Multiple Myeloma

Conclusion These observations demonstrate that the addition of vorinostat to patients with lenalidomide and dexamethasone refractory multiple myeloma was associated with moderate response and was well tolerated warranting further assessment in a larger prospective study. Teaser Lenalidomide/dexamethasone refractory patients were treated with the combination of lenalidomide, dexamethasone and vorinostat. An ORR of 27% was seen and therapy was well tolerated. This represents a treatment option in heavily pretreated myeloma.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research